Skip to content

Use of Methylphenidate in Children and Adolescents in France

Use of Methylphenidate in Children and Adolescents in France

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03371069
Enrollment
1
Registered
2017-12-13
Start date
2015-09-30
Completion date
2017-09-30
Last updated
2017-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Use of Methylphenidate in Children and Adolescents

Keywords

methylphenidate, drug utilisation study, pediatrics

Brief summary

The use of methylphenidate in children and adolescents in France from 2010 to 2015

Detailed description

To describe the use of methylphenidate in children and adolescents in France from 2010 to 2015

Interventions

OTHERusers of methylphenidate

Children and adolescents who are users of methylphenidate, 2010 to 2015

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 17 Years
Healthy volunteers
No

Inclusion criteria

* children and adolescents (0-17 years) * registered in the French Health Insurance Database from 2012-2015

Design outcomes

Primary

MeasureTime frameDescription
use of methylphenidate over time6 yearsDescribe of the use of methylphenidate over time to determine the impact of regulatory information of appropriate prescription conditions of use in September 2012

Secondary

MeasureTime frameDescription
Describe methylphenidate patterns of use over time6 yearsPharmaceutical specialties (immediate or extended release forms) prescribed by type of delivery: initial or renewals. Profile of prescribers: hospital or private practice (general practitioners, specialists) depending on type of prescription (initial or renewal); geographical distribution of the prescribers Profile of patients: sex, average age and age classes (0-23 months, 2-5 years, 6-11 years, 12-17 years), socioeconomic status, long-lasting diseases status for psychosis, severe personality disorder, mental retardation. Pattern of methylphenidate use: duration of treatment, prolonged use, interruption of treatment.
Co-prescription of methylphenidate and non-psychostimulant psychotropic drugs6 years

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026